Ware A J, Cuthbert J A, Shorey J, Gurian L E, Eigenbrodt E H, Combes B
Gastroenterology. 1981 Feb;80(2):219-24.
A prospective, double-blinded, randomized trial of corticosteroid therapy in patients with severe acute viral hepatitis has been conducted. At the same time, we have examined the prognostic significance of the presence of bridging necrosis in liver biopsies obtained from such patients as well as the predictive value of certain serologic markers. Forty-two of the 77 patients admitted to the trial were shown to have bridging necrosis on their initial biopsies. Two patients progressed to death with massive hepatic necrosis, while 5 patients developed chronic liver disease. A complicated course could not be predicted by the initial biopsy findings nor by any of the serologic markers assessed. We could not identify any clinical or epidemiologic features with prognostic impact. No advantage was demonstrated to be associated with the use of corticosteroids early in the course of severe viral hepatitis.
我们开展了一项针对重症急性病毒性肝炎患者的前瞻性、双盲、随机皮质类固醇治疗试验。同时,我们研究了此类患者肝活检中桥接坏死的存在对预后的意义以及某些血清学标志物的预测价值。在纳入试验的77例患者中,42例在初次活检时显示有桥接坏死。2例进展为伴有大块肝坏死的死亡,5例发展为慢性肝病。初始活检结果或所评估的任何血清学标志物均无法预测病情的复杂进程。我们未能确定任何具有预后影响的临床或流行病学特征。在重症病毒性肝炎病程早期使用皮质类固醇未显示出任何优势。